Provided are m-diamide compounds and a preparation method therefor and the use thereof. The m-diamide compounds have a structure represented by formula I. The m-diamide compounds of the present invention can have a high insecticidal activity at a low dose and take effect rapidly, can exert the insecticidal activity one day after application, can achieve a high insecticidal activity within three days, and have a good fast-acting property; moreover, due to the good effect at a low dose, the m-diamide compounds can reduce the damage to plants and human beings caused by excessive drug concentrations, enable less drug residue to be generated during application which is more conducive to environmental protection, and have broad application prospects.

The present invention relates to hyper-branched compounds, a method of synthesizing the hyper-branched compounds and applications of the hyper-branched compounds. The hyper-branched compounds of the present invention include hyper-branched fluorinated compounds, hyper-branched fluorinated graphene and hyper-branched amine functionalized graphene oxide.

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

Provided is a method for producing an optically active substance, the method including an asymmetric induction, wherein an asymmetry inducer is allowed to act on a chiral molecule having a half-life of enantiomeric excess of shorter than 10 hours, thereby increasing abundance of one enantiomer of the chiral molecule. According to this method, one enantiomer of a chiral molecule that is susceptible to racemization can be selectively and efficiently obtained.

Disclosed herein are compounds for activating the Reelin signaling system for the treatment of neurological disorders Further provided are compounds and methods for activating a lipoprotein receptor, such as ApoER2 or VLDLR.

Disclosed herein are compounds for activating the Reelin signaling system for the treatment of neurological disorders Further provided are compounds and methods for activating a lipoprotein receptor, such as ApoER2 or VLDLR.

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1′) wherein ring Q.sup.1 is optionally-substituted C.sub.6-10 aryl group, etc.; R.sup.1 and R.sup.2 are independently hydrogen atom, etc.; W.sup.1 is optionally-substituted C.sub.1-4 alkylene group; W.sup.2 is —NR.sup.3aC(O)— wherein R.sup.3a is hydrogen atom or C.sub.1-6 alkyl group, etc.; ring Q.sup.2 is 5- to 10-membered heteroaryl group, etc.; W.sup.3 is optionally-substituted C.sub.1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R.sup.4 is independently halogen atom, optionally-substituted C.sub.1-6 alkyl group, etc.; R.sup.5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent. ##STR00001##

The present invention provides a 1,4-disubstituted imidazole derivative of formula (1′) wherein ring Q.sup.1 is optionally-substituted C.sub.6-10 aryl group, etc.; R.sup.1 and R.sup.2 are independently hydrogen atom, etc.; W.sup.1 is optionally-substituted C.sub.1-4 alkylene group; W.sup.2 is —NR.sup.3aC(O)— wherein R.sup.3a is hydrogen atom or C.sub.1-6 alkyl group, etc.; ring Q.sup.2 is 5- to 10-membered heteroaryl group, etc.; W.sup.3 is optionally-substituted C.sub.1-4 alkylene group, etc.; n is 1, 2, 3, 4, or 5; R.sup.4 is independently halogen atom, optionally-substituted C.sub.1-6 alkyl group, etc.; R.sup.5 is hydroxy group, etc.; and a pharmacologically acceptable salt thereof, which have a potent inhibitory effect on the sphere-forming capacity of cancer cells and are useful as an orally-available anti-tumor agent. ##STR00001##

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:

##STR00001##

wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.1d, R.sub.2, R.sub.2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:

##STR00001##

wherein R.sub.1a, R.sub.1b, R.sub.1c, R.sub.1d, R.sub.2, R.sub.2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.